Archived explainer. For the current picture see today's TEM page.
Why Is TEMPUS AI INC A (TEM) Stock Down Today?
By the Top Tier Newswire AI Desk · October 7, 2026 at 8:44 AM ET · reviewed against 4 wire stories
TEMPUS AI INC A (TEM) is down -13.85% in the latest session. Our newswire has captured 4 stories on TEM across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TEM stock is down today
Tempus AI Inc A (TEM) fell 13.85% to $71.98 in early trading on October 6, 2026, marking a sharp reversal in a stock already down 14.8% over the previous eight sessions. The move followed the announcement of an expanded multi-year collaboration with Moderna and Merck to build the Sample-to-Sequencing workflow for the experimental cancer vaccine intismeran autogene (V940/mRNA-4157). While the partnership signals long-term potential, it appears to have triggered a sell-off as investors reassessed the company's near-term prospects and capital allocation.
What Happened
Tempus announced an expanded collaboration with Moderna and Merck to support potential commercialization of the individualized neoantigen therapy V940. The agreement is multi-year in duration and aims to prepare for the possible commercial launch of the treatment. However, the stock opened at $71.57, slightly below the prior close, and quickly drifted lower, hitting a session low of $69.56. The stock briefly bounced to a high of $74.94 in the first 30 minutes of trading but failed to hold that level. The session ended with the stock at $70.48, with 0.3 million shares traded, well below the 3-month average.
Separately, BTIG downgraded Personalis, citing the likelihood of a $1.5 billion acquisition by Tempus. This added to the day's volatility as investors considered the broader implications of Tempus's strategic direction and capital use.
What The Data Shows
Over the past 90 days, insiders have sold 26 times, totaling $86.5 million, with the most recent filing on September 29. The stock has printed 64 fresh 52-week lows on October 6, while also hitting seven 52-week highs. Options activity showed unusual put premium of $456,000, with the largest single print at $350,000. The stock currently trades within its 52-week range of $40.77 to $104.32 and has a market cap of $15.1 billion. Despite a 50.4% year-to-date revenue increase, the company remains unprofitable with a net margin of -17.8% and an earnings per share (TTM) of -1.43.
What To Watch
Investors should monitor Tempus’s upcoming earnings report if scheduled, as well as the breadth of analyst coverage and further developments in its partnership with Moderna and Merck.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TEM · today's session (5-min) · -1.81% vs prior close · updated 3:33 PM ETAI sentiment, last 36h · averaged over 4 stories · 56/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoMarketChameleonBULLISH 67Product/PR
Tempus Broadens Collaboration With Moderna and Merck to Build the Sample-to-Sequencing Workflow for V940
Tempus (NASDAQ: TEM) announced an expanded, multi-year collaboration with Moderna and Merck to support potential commercialization preparations for intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated with KEYTRUDA in melanoma and other cancers. Tempus will manage tumor and blood sample collection/transfer for next-generation sequencing and, subject to regulatory approvals, provide NGS services to support therapy design and manufacturing; financial terms…
7h agoThe FlyBULLISH 63Product/PR
Tempus AI announces multi-year collaboration with Moderna, Merck
7h agoStockTitanBULLISH 63Product/PR
Tempus Announces Multi-Year Collaboration with Moderna and Merck
1d agoSeeking AlphaBEARISH 32M&A
Personalis downgraded at BTIG on likely Tempus takeover
Personalis (PSNL) stock slips as BTIG downgrades the cancer test maker, noting that Tempus AI (TEMP) will complete its $1.5B M&A deal with the company. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →